Engfeldt Torun, Tran Thuy, Orlova Anna, Widström Charles, Feldwisch Joachim, Abrahmsen Lars, Wennborg Anders, Karlström Amelie Eriksson, Tolmachev Vladimir
School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden.
Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1843-53. doi: 10.1007/s00259-007-0474-6. Epub 2007 Jun 13.
Monitoring HER2 expression is crucial for selection of breast cancer patients amenable to HER2-targeting therapy. The Affibody molecule Z(HER2:342) binds to HER2 with picomolar affinity and enables specific imaging of HER2 expression. Previously, Z(HER2:342) with the additional N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labelled with (99m)Tc and demonstrated specific targeting of HER2-expressing xenografts. However, hepatobiliary excretion caused high radioactivity accumulation in the abdomen. We investigated whether the biodistribution of Z(HER2:342) can be improved by substituting glycyl residues in the chelating sequence with more hydrophilic seryl residues.
The Affibody molecule Z(HER2:342), carrying the chelators mercaptoacetyl-glycyl-seryl-glycyl (maGSG), mercaptoacetyl-glycyl-D: -seryl-glycyl [maG(D-S)G] and mercaptoacetyl-seryl-seryl-seryl (maSSS), were prepared by peptide synthesis and labelled with (99m)Tc. The differences in the excretion pathways were evaluated in normal mice. The tumour targeting capacity of (99m)Tc-maSSS-Z(HER2:342) was studied in nude mice bearing SKOV-3 xenografts and compared with the capacity of radioiodinated Z(HER2:342).
A shift towards renal excretion was obtained when glycine was substituted with serine in the chelating sequence. The radioactivity in the gastrointestinal tract was reduced threefold for the maSSS conjugate in comparison with the maGGG conjugate 4 h post injection (p.i.). The tumour uptake of (99m)Tc-maSSS-Z(HER2:342) was 11.5 +/- 0.5% IA/g 4 h p.i., and the tumour-to-blood ratio was 76. The pharmacokinetics and uptake characteristics of technetium-labelled Z(HER2:342) were better than those of radioiodinated Z(HER2:342).
The introduction of serine residues in the chelator results in better tumour imaging properties of the Affibody molecule Z(HER2:342) compared with glycyl-containing chelators and is favourable for imaging of tumours and metastases in the abdominal area.
监测HER2表达对于选择适合HER2靶向治疗的乳腺癌患者至关重要。亲和体分子Z(HER2:342)以皮摩尔亲和力与HER2结合,能够对HER2表达进行特异性成像。此前,带有额外N端巯基乙酰-甘氨酰-甘氨酰-甘氨酰(maGGG)序列的Z(HER2:342)用(99m)Tc标记,并显示出对表达HER2的异种移植瘤的特异性靶向。然而,肝胆排泄导致腹部放射性高聚集。我们研究了用更具亲水性的丝氨酰残基取代螯合序列中的甘氨酰残基是否能改善Z(HER2:342)的生物分布。
通过肽合成制备携带螯合剂巯基乙酰-甘氨酰-丝氨酰-甘氨酰(maGSG)、巯基乙酰-甘氨酰-D-丝氨酰-甘氨酰[maG(D-S)G]和巯基乙酰-丝氨酰-丝氨酰-丝氨酰(maSSS)的亲和体分子Z(HER2:342),并用(99m)Tc标记。在正常小鼠中评估排泄途径的差异。在携带SKOV-3异种移植瘤的裸鼠中研究(99m)Tc-maSSS-Z(HER2:342)的肿瘤靶向能力,并与放射性碘化的Z(HER2:342)的能力进行比较。
当螯合序列中的甘氨酸被丝氨酸取代时,排泄途径向肾脏排泄转变。注射后4小时(p.i.),与maGGG偶联物相比,maSSS偶联物在胃肠道中的放射性降低了三倍。(99m)Tc-maSSS-Z(HER2:342)在注射后4小时的肿瘤摄取为11.5±0.5%IA/g,肿瘤与血液的比值为76。锝标记的Z(HER2:342)的药代动力学和摄取特性优于放射性碘化的Z(HER2:342)。
与含甘氨酰的螯合剂相比,在螯合剂中引入丝氨酸残基可使亲和体分子Z(HER2:342)具有更好的肿瘤成像特性,有利于腹部肿瘤和转移灶的成像。